Icon Government And Public Health Solutions, Inc.
Icon Government And Public Health Solutions, Inc. is a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries, specializing in clinical research and offering end-to-end services from compound selection to Phase I-IV clinical trials. It is a foreign-owned, for-profit organization, registered in the System for Award Management (SAM) since 2001.
Icon Government And Public Health Solutions, Inc. has been awarded numerous prime and subcontracts by federal agencies, primarily the Department of Health and Human Services (HHS), Department of Defense (DoD), and National Institutes of Health (NIH). The majority of its contracts involve providing comprehensive clinical trial planning and execution services for medical countermeasures like vaccines, therapeutics, and other products against infectious diseases, chemical/biological threats, and public health emergencies like COVID-19. This includes activities such as protocol development, site selection, regulatory submissions, participant recruitment, data management, quality assurance, and reporting. Icon leverages its network of research sites and team of clinical research associates, scientists, nurses, and project managers to conduct domestic and international trials across all phases. In addition to HHS and DoD, Icon has supported clinical research programs for agencies like the Defense Health Agency and U.S. Army Medical Command. While most awards utilize no set-asides, Icon has participated in socioeconomic set-asides on certain subcontracts.
Icon Government And Public Health Solutions, Inc. holds several prominent indefinite delivery vehicles focused on clinical trials and research support. These include a $400 million Clinical Trials Planning and Execution IDIQ from HHS's Office of the Assistant Secretary for Preparedness and Response enabling rapid task order issuance for medical countermeasure studies, a $545 million Comprehensive and Rapid Response to NIAID Research Programs IDIQ to support the full range of basic research to clinical trials for the NIH's National Institute of Allergy and Infectious Diseases, and a $346 million Early Phase Clinical Trial Units IDIQ providing domestic and international Phase 0 to Phase II trials of investigational infectious disease products for NIAID. Icon was also awarded a $6 million Federal Supply Schedule contract allowing streamlined procurement of professional scientific and technical services across over 70 labor categories. Clients can acquire clinical trial, regulatory, data management, manufacturing, and other services mapped to hourly labor rates under the GSA schedule.
JHJ7HXD5XR47 541715
Not listed 731 Arbor Way #100, Blue Bell, PA 19422, USA
9/27/01 8/28/25 Dynport Vaccine Company LLC
Dynport Vaccine Company LLC DVC Segment Division is a subsidiary of General Dynamics Corp. that provides a range of research, development, manufacturing, and testing services to support biopharmaceutical products targeting infectious diseases.
Through past federal contracts, Dynport has provided preclinical development, clinical trials, diagnostic testing, vaccine stability evaluations, and cGMP production services in support of therapeutics and vaccines for emerging infectious diseases. Major customers include NIH, HHS, and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. Prime contract awards have funded process development, assay validation, pilot manufacturing, Phase I trials, and stability testing of vaccine candidates over 1-5 year periods. Subcontracts have supported clinical trials and CGMP cell bank production. Most awards utilize firm fixed price or cost plus fixed fee structures without set asides. Places of performance are centered at Dynport's Maryland-based locations.
Dynport holds several infectious disease-focused IDVs as a prime contractor, most notably the $30 million Preclinical Services for Biopharmaceutical Product Development contract from NIH-NIAID. This single-award IDIQ covers process development, assay validation, CGMP production, and regulatory documentation to support candidate vaccines and therapies from early inception through preclinical advancement. Dynport also holds the $36 million Diagnostic Pre-Clinical Services Program contract, which funds development processes needed to bring candidate infectious disease diagnostics to market. Additionally, Dynport is one of multiple awardees under the $346 million Early Phase Clinical Trial Units IDIQ, which has funded Phase I trial services under cost plus fixed fee delivery orders to date.
LXNEGTYDR755 541714
Not listed 110 Thomas Johnson Dr, Frederick, MD 21702, USA
4/2/02 12/4/25 Duke University
Duke University is a top-ranked global institution dedicated to expanding the frontiers of knowledge and applying it in service to society. The university is home to about 13,000 undergraduate and graduate students and has a world-class faculty. Duke University's Office of Research Administration Division oversees and provides administrative support for the university's sponsored research and educational grants and contracts from the federal government and other sponsors. Through federal contract and grant awards, Duke University provides a diverse array of goods and services to various government agencies, including clinical research, biomedical studies, educational services, and advanced technological development.
Duke University has been awarded numerous federal contracts to provide a wide range of goods and services. As a prime contractor for the Centers for Disease Control and Prevention (CDC), Duke has conducted clinical research and immunization safety assessment services under an indefinite delivery indefinite quantity (IDIQ) vehicle. The university has also provided executive training services to the Federal Emergency Management Agency (FEMA). Duke has delivered brain research, educational services, and infrastructure support through awards from agencies like the Department of Veterans Affairs (VA), Defense Advanced Research Projects Agency (DARPA), National Aeronautics and Space Administration (NASA), and Department of the Navy. Many of Duke's contract awards have been set-aside free, without any specific socioeconomic designations. The university has collaborated with various partners on both prime and subcontracts to deliver these services.
Duke University has been awarded numerous federal grants to conduct critical research across various disciplines. These grants have enabled Duke to provide services spanning biomedical research, brain and neuroscience studies, cancer research, cardiovascular disease research, gene therapy development, climate and environmental science, behavioral and social science research, and many other areas. Key federal grant programs supporting Duke's research include extramural programs from the National Institutes of Health (NIH) institutes and centers, as well as programs from the National Science Foundation (NSF), Department of Defense agencies like the Defense Health Agency, and other federal research agencies. Duke has frequently collaborated with other universities, research institutions, and industry partners as either a prime or sub-awardee on these grants, contributing to groundbreaking research and scientific advancements.
The Defense Advanced Research Projects Agency (DARPA) awarded Duke University an Other Transaction (OT) indefinite delivery vehicle (IDV) contract called MEASQUIT, valued at $1,000,000, to provide research and development services related to measurement-based quantum information and transduction. No set-aside designations were used for this IDV award to Duke's Office of Research Administration Division, which serves as the prime contractor. The full scope of services Duke will provide under this IDV is not specified, but it aligns with Duke's expertise across various research domains applicable to government agencies. This IDV demonstrates Duke's capability to engage in cutting-edge research and development projects that have potential applications in advanced technologies for defense and national security purposes.
TP7EK8DZV6N5 611310
Not listed 2200 W Main St, Durham, NC 27705, USA
2/26/02 9/28/25